2019 Global Treatment Resistant Depression Clinical Trials Review, H2: Overview of Trial Numbers & their Average Enrollment in Top Countries Conducted Across the Globe - ResearchAndMarkets.com

The "Treatment Resistant Depression Global Clinical Trials Review, H2, 2019" clinical trials has been added to ResearchAndMarkets.com's offering.

Summary

The clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2019 provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Countries Contributing to Clinical Trials in Middle East and Africa
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Treatment Resistant Depression Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Treatment Resistant Depression
• Oct 15, 2019: Relmada Therapeutics announces top-line results from REL-1017 phase 2 study in individuals with treatment resistant depression
• Oct 14, 2019: Relmada Therapeutics to announce results of phase 2 study of REL-1017 for treatment resistant depression and conduct Conference Call
• Clinical Trial Profile Snapshots

Appendix

• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About the Author
• Contact Us
• Source

Companies Mentioned

• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• AstraZeneca Plc
• Bristol-Myers Squibb Co
• Eli Lilly and Co
• Alkermes Plc
• The Lundbeck Foundation
• Evotec SE
• Relmada Therapeutics Inc
• BrainCells Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/duny5y

View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005532/en/